The patent battle between US pharmaceuticals major Merck Sharp and Dohme (MSD) and Indian firm Glenmark Pharmaceuticals over the sale of diabetes drug Januvia comes up for hearing in the Delhi High Court on Thursday.
Mark Chataway‘s insight:
MSD had done the right thing here: the medicine in India cost about 20% of what it cost in Western markets. MSD had also licensed an Indian brand of the drug. If thisthe Court tolerates this kind of treatment of comapnies which use responsible pricing, don’t expect many others to try it
See on ibnlive.in.com
